This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Abbvie
AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
DitchCarbon Score
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbvie's score of 62 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbvie's reported carbon emissions
In 2024, AbbVie reported total carbon emissions of approximately 300,072,000 kg CO2e for Scope 1 and 122,287,000 kg CO2e for Scope 2. This marks a reduction from 2023, where emissions were about 328,259,000 kg CO2e for Scope 1 and 131,232,000 kg CO2e for Scope 2. AbbVie has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. This commitment includes increasing the sourcing of renewable electricity from 29.5% in 2021 to 100% by 2030. The company also aims for a 25% reduction in absolute carbon emissions by 2025, compared to a 2015 baseline. AbbVie is committed to ensuring that 79.1% of its suppliers, based on emissions from purchased goods and services, capital goods, and upstream transportation, will have science-based targets by 2027. AbbVie’s climate initiatives are aligned with the Science Based Targets initiative (SBTi), which confirms that their targets are consistent with the reductions required to limit global warming to 1.5°C. The company has also pledged to achieve net-zero emissions by 2050. Overall, AbbVie is actively working towards significant emissions reductions while enhancing its sustainability practices across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbvie is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
